Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Chi-Med Starts Trial of Sulfatinib in Thyroid Cancer Patients

publication date: Mar 2, 2016
Hutchison China MediPharma, the novel drug discovery division of Chi-Med, has begun a China Phase II trial of sulfatinib (HMPL-012) in patients with thyroid cancer. The drug candidate is already undergoing four other trials for patients with neuroendocrine cancer in both China and the US. Sulfatinib has a dual anti-angiogenesis mechanism, attacking VEGFR and FGFR1 tyrosine kinase receptors. The first patient in the latest trial was dosed on March 1, 2016. More details....

Stock Symbol: (AIM: HCM)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital